hypoactive sexual desire disorder Archives - CDR

Valeant to buy Sprout Pharmaceuticals for $1 billion

August 20, 2015 by Chain Drug Review Addyi, Anne Whitaker, Cindy Whitehead, female sexual dysfunction, flibanserin, HSDD, hypoactive sexual desire disorder, J. Michael Pearson, Sprout Pharmaceuticals, Valeant Pharmaceuticals Pharmacy, Supplier News

LAVAL, Quebec — Valeant Pharmaceuticals International Inc. plans to acquire Sprout Pharmaceuticals Inc., the maker of a just-approved drug for sexual desire disorder in women, for about $1 billion in cash. Valeant said Thursday that it expects to close the deal in the third quarter of this year, pending customary closing conditions and regulatory approval.

FDA OKs first drug for women’s sexual desire disorder

August 19, 2015 by Chain Drug Review Addyi, CDER, Center for Drug Evaluation and Research, Cindy Whitehead, female sexual dysfunction, Food and Drug Administration, HSDD, hypoactive sexual desire disorder, Janet Woodcock, Sprout Pharmaceuticals Pharmacy, Supplier News

RALEIGH, N.C. — Sprout Pharmaceuticals Inc. has gained Food and Drug Administration clearance to market Addyi, which the company calls the first FDA-approved medication for hypoactive sexual desire disorder (HSDD) in women. Sprout said late Tuesday that Addyi (flibanserin, 100 mg) is slated to be released by Oct. 17. “It has been a remarkable journey to